Carol Burns has been named VP of product and business development for Embrella Cardiovascular (Malvern, Pennsylvania). Most recently, Burns was director, international sales and marketing at Animas. Embrella is an early stage company dedicated to developing a unique, proprietary system to enhance embolic cerebral protection.

John Toole, MD, PhD, has been promoted from senior VP of clinical research to senior VP of corporate development at Gilead Sciences (Foster City, California). Gilead Sciences is a biopharmaceutical company that helps advance the care of patients suffering from life-threatening diseases.

Robert Gudbranson has been named senior VP and CFO of Invacare (Elyria, Ohio), effective April 1. Most recently, Gudbranson was VP of strategic planning and acquisitions for Lincoln Electric Holdings. Invacare makes home and long-term care medical products.

Pathway Medical Technologies (Kirkland, Washington) announced that Paul Buckman has been named as the new chairman. He replaces Dan Galles, who has been acting board chairman since late 2006. Buckman, who has worked in the medical device industry for over 30 years, is currently CEO and a director of Devax. Pathway makes medical devices for the treatment of arterial disease.